These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1918422

  • 1. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL.
    J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
    [Abstract] [Full Text] [Related]

  • 2. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS, Barklage NE.
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [Abstract] [Full Text] [Related]

  • 3. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR.
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [Abstract] [Full Text] [Related]

  • 4. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.
    Hewlett WA, Vinogradov S, Agras WS.
    J Clin Psychopharmacol; 1992 Dec; 12(6):420-30. PubMed ID: 1474179
    [Abstract] [Full Text] [Related]

  • 5. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
    Hoehn-Saric R, McLeod DR, Zimmerli WD, Hipsley PA.
    J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
    Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL.
    J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
    [Abstract] [Full Text] [Related]

  • 7. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT, Hill JL, Murphy DL.
    Psychopharmacol Bull; 1990 Jun; 26(2):211-4. PubMed ID: 2236458
    [Abstract] [Full Text] [Related]

  • 8. Double-blind controlled study in phobias and obsessions.
    Karabanow O.
    J Int Med Res; 1977 Jun; 5 Suppl 5():42-8. PubMed ID: 340306
    [Abstract] [Full Text] [Related]

  • 9. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ.
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [Abstract] [Full Text] [Related]

  • 10. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.
    Rasmussen SA.
    Am J Psychiatry; 1984 Oct; 141(10):1283-5. PubMed ID: 6435460
    [Abstract] [Full Text] [Related]

  • 11. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
    Simeon JG, Thatte S, Wiggins D.
    Psychopharmacol Bull; 1990 Oct; 26(3):285-90. PubMed ID: 2274627
    [Abstract] [Full Text] [Related]

  • 12. Worldwide use of clomipramine.
    Trimble MR.
    J Clin Psychiatry; 1990 Aug; 51 Suppl():51-4; discussion 55-8. PubMed ID: 2199435
    [Abstract] [Full Text] [Related]

  • 13. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J, Kaplan Z, Benjamin J.
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [Abstract] [Full Text] [Related]

  • 14. The pharmacotherapy of moral or religious scrupulosity.
    Fallon BA, Liebowitz MR, Hollander E, Schneier FR, Campeas RB, Fairbanks J, Papp LA, Hatterer JA, Sandberg D.
    J Clin Psychiatry; 1990 Dec; 51(12):517-21. PubMed ID: 2258366
    [Abstract] [Full Text] [Related]

  • 15. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G, Noshirvani H, Marks I, Monteiro W, Lelliott P.
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [Abstract] [Full Text] [Related]

  • 16. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL.
    J Clin Psychopharmacol; 1992 Feb; 12(1):11-8. PubMed ID: 1552034
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH.
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [Abstract] [Full Text] [Related]

  • 18. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG, Bouhassira M, Lancrenon S.
    Encephale; 2000 Oct; 26(6):73-83. PubMed ID: 11217541
    [Abstract] [Full Text] [Related]

  • 19. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR, Jones B, Olson S, Perel JM.
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [Abstract] [Full Text] [Related]

  • 20. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G.
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.